The EU-funded research project BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) kicks off its activities with the aim of improving the lives of patients affected by the two most common inflammatory skin conditions. Addressing key unmet needs in treating atopic dermatitis and psoriasis by analysing data from more than 50 000 patients, the five-year project will have a broad impact on disease understanding, patient care and future therapies.The team comprises 26 academic and five industry partners as well as five patient organisations. By analysing the largest collection of patient data ever and performing advanced molecular investigations at the single cell level and in the tissue context, they aim at identifying biomarkers for variations in disease outcome.
The European Innovative Medicines Initiative (IMI) and the participating pharma companies provide EUR 20.8 million funding for the first IMI project in the field of dermatology. The Laboratory for Experimental Dermatology, dept. Of Dermatology headed by Ellen van den Bogaard, theme Inflammatory diseases, leads the research on the experimental validation and functional analysis of identified biomarkers by using advanced organotypic skin models and receives a grant of €258,000.
Related news items
Radboudumc Master Prize for Mark van Goor18 June 2019
Mark van Goor, theme Renal disorders, received the Radboudumc Master Prize for his MSc thesis entitled “High-resolution structure of the renal calcium channel TRPV5 revealed with cryo-EM”, which was based on his internship at the lab of Prof. Yifan Cheng, USA.read more
Exome sequencing in routine diagnostics: a generic test for 254 patients with primary immunodeficiencies18 June 2019
Exome sequencing may provide a genetic diagnosis in a significant number of patients in a single genetic test. Alexander Hoischen and Mihai Netea, theme Infectious diseases and global health, and colleagues, published their results in Genome Medicine.read more
Lowering cholesterol is not enough to reduce hyperactivity of the immune system14 June 2019
In Cell Metabolism, Siroon Bekkering, theme Vascular damage, and colleagues, provides a novel potential explanation for the residual cardiovascular risk, related to persistent activation of the immune system in patients with hypercholesterolemia who are treated with statins.read more